

# Jordi Pegueroles

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4097461/jordi-pegueroles-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52  
papers

1,048  
citations

18  
h-index

32  
g-index

62  
ext. papers

1,435  
ext. citations

6.8  
avg, IF

3.74  
L-index

#	Paper	IF	Citations
52	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet Neurology, The</i> , <b>2018</b> , 17, 860-869	24.1	105
51	Cerebrospinal fluid Amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. <i>Annals of Neurology</i> , <b>2014</b> , 76, 223-30	9.4	88
50	Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet, The</i> , <b>2020</b> , 395, 1988-1997	40	74
49	YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies. <i>Journal of Neuroinflammation</i> , <b>2017</b> , 14, 118	10.1	69
48	APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls. <i>Oncotarget</i> , <b>2015</b> , 6, 26663-74	3.3	67
47	Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. <i>Molecular and Cellular Proteomics</i> , <b>2019</b> , 18, 546-560	7.6	66
46	Relationship between cortical thickness and cerebrospinal fluid YKL-40 in prodementia stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 2018-23	5.6	64
45	Synaptic phosphorylated Synuclein in dementia with Lewy bodies. <i>Brain</i> , <b>2017</b> , 140, 3204-3214	11.2	64
44	Cortical microstructural changes along the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 340-351	1.2	60
43	Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. <i>Annals of Clinical and Translational Neurology</i> , <b>2019</b> , 6, 1815-1824	5.3	46
42	Longitudinal brain structural changes in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 499-509	1.2	38
41	Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study. <i>Oncotarget</i> , <b>2018</b> , 9, 34691-34698	3.3	37
40	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. <i>Brain</i> , <b>2019</b> , 142, 1121-1133	11.2	32
39	Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease. <i>Oncotarget</i> , <b>2017</b> , 8, 104706-104716	3.3	31
38	Nanoscale structure of amyloid-β plaques in Alzheimer's disease. <i>Scientific Reports</i> , <b>2019</b> , 9, 5181	4.9	28
37	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2019</b> , 5, 597-609	6	26
36	Challenges associated with biomarker-based classification systems for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2018</b> , 10, 346-357	5.2	25

35	Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2020</b> , 7,	9.1	21
34	Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17, 618-628	1.2	11
33	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , <b>2021</b> , 12, 4304	17.4	11
32	Association of Apolipoprotein E e4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. <i>JAMA Neurology</i> , <b>2021</b> , 78, 937-947	17.2	11
31	Cortical microstructure in the amyotrophic lateral sclerosis-frontotemporal dementia continuum. <i>Neurology</i> , <b>2020</b> , 95, e2565-e2576	6.5	10
30	Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome. <i>Molecular Neurodegeneration</i> , <b>2020</b> , 15, 46	19	10
29	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2021</b> , 92, 1206-1214	5.5	10
28	APP-derived peptides reflect neurodegeneration in frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , <b>2019</b> , 6, 2518-2530	5.3	10
27	Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2018</b> , 64, 58-67	5.6	7
26	The pitfalls of biomarker-based classification schemes. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 1072-1074	1.2	5
25	Distinctive Oculomotor Behaviors in Alzheimer's Disease and Frontotemporal Dementia. <i>Frontiers in Aging Neuroscience</i> , <b>2020</b> , 12, 603790	5.3	5
24	AMYQ: An index to standardize quantitative amyloid load across PET tracers. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17, 1499-1508	1.2	4
23	Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2020</b> , 12, e12052	5.2	3
22	Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome. <i>Annals of Neurology</i> , <b>2021</b> , 90, 407-416	9.4	3
21	Agreement between 18F-Florbetapir PET imaging and cerebrospinal fluid A $\beta$ -42, A $\beta$ -40, tTau and pTau measured on the LUMIPULSE G fully automated platform		2
20	Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2212910	10.4	2
19	VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 119	9	1
18	Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. <i>Translational Neurodegeneration</i> , <b>2021</b> , 10, 50	10.3	1

17 Cortical microstructure in primary progressive aphasia: a multicenter study.. *Alzheimer's Research and Therapy*, **2022**, 14, 27 9 0

16 AmyQ: An index to accurately measure cerebral amyloid load. *Alzheimer's and Dementia*, **2020**, 16, e039735

15 Oligodendroglial alterations in FTD caused by C9orf72 expansion. *Alzheimer's and Dementia*, **2020**, 16, e040196 1.2

14 Transcriptome characterization of the motor cortex suggests microglial-related key events due to TDP-43 aberrant inclusions. *Alzheimer's and Dementia*, **2020**, 16, e042953 1.2

13 1H-MRS signature in Alzheimer disease in Down syndrome. *Alzheimer's and Dementia*, **2020**, 16, e0433461.2

12 [P1866]: WEIGHT LOSS MIGHT BE A NON-COGNITIVE SIGN OF PRECLINICAL ALZHEIMER'S DISEASE **2017**, 13, P399-P400

11 [P3074]: STRUCTURAL CORRELATES OF ALZHEIMER'S DISEASE AND AGING IN DOWN SYNDROME: AN MRI STUDY **2017**, 13, P1048-P1048

10 [P4805]: CORTICAL MICROSTRUCTURAL CHANGES IN FRONTOTEMPORAL LOBAR DEGENERATION: A NEW IMAGING BIOMARKER **2017**, 13, P1533

9 P3-230: CSF AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD **2014**, 10, P715-P715

8 IC-P-217: CSF AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD **2014**, 10, P117-P117

7 P2-424: Obesity is Associated With Increased CSF Phospho-TAU Levels and Cognitive Decline in Healthy Elderly **2016**, 12, P807-P807

6 IC-P-148: THE CORTICAL MICROSTRUCTURAL SIGNATURE OF ALZHEIMER'S DISEASE **2019**, 15, P119-P120

5 O2-09-01: THE NATURAL HISTORY OF ALZHEIMER'S DISEASE IN DOWN SYNDROME **2019**, 15, P558-P560

4 P2-262: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM **2018**, 14, P777-P777

3 P3-394: CORTICAL MEAN DIFFUSIVITY MAY BE MORE SENSITIVE IN DETECTING STRUCTURAL CHANGES IN FRONTOTEMPORAL DEMENTIA THAN CORTICAL THICKNESS **2018**, 14, P1248-P1249

2 P2-230: CHALLENGES ASSOCIATED WITH BIOMARKER-BASED CLASSIFICATIONS SYSTEMS FOR ALZHEIMER'S DISEASE **2018**, 14, P756-P757

1 Feasibility and Long-Term Compliance to Continuous Positive Airway Pressure Treatment in Adults With Down Syndrome, a Genetic Form of Alzheimer's Disease.. *Frontiers in Neuroscience*, **2022**, 16, 838412<sup>51</sup>